SOURCE: U.S. BioDefense, Inc.

May 30, 2007 09:30 ET

U.S. BioDefense Retains Equity Solutions for Business Development and Growth Strategy

CITY OF INDUSTRY, CA--(Marketwire - May 30, 2007) - U.S. BioDefense, Inc. (OTCBB: UBDE) announces Equity Solutions, Inc. has been retained to provide business development services.

Equity Solutions will assist U.S. BioDefense in identifying:

--  New Technologies
--  Key Personnel
--  Vertical Markets
--  Licensing Opportunities
--  Distribution Channels
--  New Market Opportunities
    

In addition Equity Solutions will assist in creating marketing plans and strategic sales initiatives for technology that is acquired by U.S. BioDefense.

David Chin, CEO of U.S. BioDefense, stated, "Our company possesses a solid base to grow and is confident Equity Solutions will assist us with future development and acquisition of customers in new market segments."

"This is a great opportunity for Equity Solutions to support the company's current efforts by increasing its presence in the homeland defense industry and focusing on homeland defense technology markets," said Eddie Cruz, CEO of Equity Solutions.

Recently, the company announced it has signed a letter of intent to license a Biochemical Defense System developed by Shine Holdings, Inc. Under this agreement, U.S. BioDefense expects to secure an exclusive licensing agreement from Shine Holdings. The technology focuses on safeguarding domestic water supplies from potential bioweapon agents such as anthrax, botulism, tularemia, and viral hemorrhagic fevers (VHFs).

About U.S. BioDefense, Inc.

U.S. BioDefense is a Department of Defense Central Contractor that researches, develops, and commercializes homeland security and leading-edge biotechnologies. U.S. BioDefense is focused on transferring, researching, and commercializing groundbreaking technologies from Universities, Research Labs, Fortune 500 Companies, and Government Agencies. Through its subsidiary Emergency Disaster Systems (EDS), the company operates its Emergency Preparedness Program as part of its Homeland Security division. U.S. BioDefense is focused on developing EDS as an industry leader in the disaster mitigation and preparedness arena, an underserved market that could see consumer spending of over 24 billion dollars in 2007.

Forward-Looking Statement

This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of management of U.S. BioDefense, Inc., and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors, and other factors affecting the operation of the businesses of U.S. BioDefense, Inc. U.S. BioDefense, Inc. is under no obligation to, and expressly disclaims any such obligation to, update or alter the respective forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information

  • Contact:

    David Chin
    President
    U.S. BioDefense, Inc.
    Tel: (626) 961-0562